Peter McCullough on health: what the evidence says · JRE #1747

What the evidence says 01 / RECORD

Public records of US government monoclonal antibody procurement for COVID-19 in 2020-2021 show purchase volumes far below the 100 million doses purchased and 500 million on order that McCullough describes. Under Operation Warp Speed, the government's initial 2020 agreements were for roughly 300,000 doses of Eli Lilly's bamlanivimab and roughly 300,000 doses of Regeneron's antibody cocktail, expanding through January 2021 to bring the Regeneron total to about 1.5 million doses and Lilly's agreements to a few million treatment courses; by early 2021 total federal monoclonal antibody purchases across manufacturers were on the order of two million doses, not hundreds of millions. Later reporting on monoclonal antibody oversupply relative to utilization (2021-2022) likewise describes federal inventories in the hundreds of thousands to under one million doses for individual products, not a 500-million-dose order. No public HHS, BARDA, GAO, or company disclosure has been identified that supports purchase or order figures in the hundreds of millions of doses for COVID-19 monoclonal antibodies. The claim appears to substantially overstate actual procurement volumes, by roughly two orders of magnitude.